Loading...
•
Sep 30, 2021
ADMA Biologics Q3 2021 Earnings Report
ADMA Biologics reported record third quarter revenue and achieved first-time positive gross profit.
Key Takeaways
ADMA Biologics reported a 101% increase in revenue compared to Q3 2020, reaching $20.7 million. The company achieved a positive gross profit for the first time and narrowed net losses quarter-over-quarter. They also strengthened their cash position through a public equity offering.
Achieved record third quarter 2021 total revenues of $20.7 million, a 101% increase over third quarter 2020.
Generated a positive gross profit for the first time in Company history.
Narrowed sequential net quarterly losses.
Closed an underwritten public offering, raising approximately $53.9 million, net of all underwriting discounts and expenses.
Forward Guidance
ADMA anticipates continued commercial execution and remains committed to unlocking the yet-to-be-realized fair value that this asset base now commands.
Positive Outlook
- The company is on track to have 10 or more plasma collection facilities FDA-licensed by year-end 2023.
- The VanRx approval will also enable ADMA to explore potentially accretive contract manufacturing opportunities with third parties not currently contemplated in ADMA’s financial guidance.
- ADMA’s in-house fill-finish capabilities position the Company as the only U.S.-domiciled fractionator of plasma-derived products with complete end-to-end control of its critical manufacturing functions.
- The anticipated yield enhancement resulting from the recent Persona® implementation, in combination with the Company’s growing BioCenters network, has ADMA well-positioned to achieve source plasma self-sufficiency and contribute to quarter-over-quarter revenue and plasma collections growth throughout 2021 and beyond.
- ADMA continues to actively engage prospective debt lenders to potentially raise additional, non-dilutive capital, which if successful, has the potential to fund the Company to profitability.
Challenges Ahead
- There are many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...